13F Holdings
中文EN

ELOX Eloxx Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1035354 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.6%
ROA-27.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets29.5%
Debt / equity0.00x
Current ratio3.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.17x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$6.36M$0——
R&D expense$3.06M$3.58M$8.60M$23.73M$22.90M
SG&A expense$3.38M$5.25M$8.69M$10.69M$20.45M
Operating income-$6.44M-$2.47M-$17.29M-$34.42M-$66.02M
Pretax income-$6.00M-$3.14M-$17.05M-$36.06M-$66.73M
Income tax$0$0$0$0$0
Net income-$6.00M-$3.14M-$17.05M-$36.06M-$66.73M
EBITDA-$6.44M-$2.43M-$17.18M-$34.34M-$65.90M
EPS (basic)-0.49-0.84-6.63-16.65-38.15
EPS (diluted)-0.49-0.84-6.63-16.65-38.15
Weighted avg. shares (diluted)12.35M3.76M2.57M2.17M1.75M
Balance sheet
Cash & equivalents$4.79M$111,000$1.13M$19.21M$42.27M
Current assets$5.27M$2.98M$1.55M$20.13M$43.48M
PP&E, net$0$0$35,000$169,000$216,000
Total assets$5.27M$2.98M$1.71M$21.12M$45.14M
Current liabilities$17.18M$27.31M$22.70M$23.09M$9.96M
Short-term debt$1.00M$6.52M$2.22M$3.98M$0
Long-term debt$0$0$1.61M$8.56M$12.00M
Total debt$1.00M$6.52M$3.83M$12.54M$12.00M
Total liabilities$17.18M$27.31M$24.31M$31.78M$22.75M
Shareholders' equity-$11.91M-$24.34M-$22.60M-$10.66M$22.38M
Net debt-$3.79M$6.41M$2.70M-$6.67M-$30.27M
Shares outstanding435,4323.53M3.14M2.17M2.17M
Cash flow statement
Operating cash flow-$6.33M-$4.71M-$14.34M-$31.84M-$35.00M
Capital expenditure———$66,000$89,000
Free cash flow———-$31.91M-$35.09M
Investing cash flow$1,000$38,000$309,000-$66,000$2.06M
Financing cash flow$11.00M$3.44M-$4.08M$8.81M$50.79M
Depreciation & amortization$0$35,000$113,000$77,000$114,000
Stock-based compensation$235,000$541,000$1.97M$3.02M$9.17M

Free plan shows the latest 5 periods; Pro shows all 30 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.